

BIOGRAPHICAL SKETCH

NAME: GIANLUIGI GIANNELLI

eRA COMMONS USER NAME (credential, e.g., agency login):

ORCID: (0000-0002-5140-8060)

Web of Science Research ID: A-8169-2012

Bibliometric Indicators: H-index = 68 // Number of publications = 519 // Number of citations = over 18600
(source: Google Scholar)POSITION TITLE: **Scientific Director** at IRCCS "Saverio de Bellis" in Castellana Grotte**EDUCATION/TRAINING**

INSTITUTION AND LOCATION	DEGREE	Completion Date MM/YYYY	FIELD OF STUDY
University of Bari	Master's Degree	11/1987	Medicine and Surgery
University of Bari	Specialization	07/1992	Internal Medicine

A. Personal Statement

Prof. Gianluigi Giannelli leads the coordination and supervision of the Units and activities of the whole project. In this project, the complementary expertise and knowledge of the investigators involved is a major strength that will guarantee the reliability and feasibility of the proposed aims. The project is founded on a close collaboration between the clinical (Medical Oncology, Surgery, Pathological Anatomy) and research Units (Experimental Oncology and Bioinformatics) of the Institute.

B. Positions, Scientific Appointments, and Honors**Research and Academic Activities**

- **1990-1993:** Researcher with Fellowship at the Virology Institute, University of Rome "La Sapienza"
- **1993-1994:** Researcher with Fellowship at the University of Turin, Department of Biomedical Sciences and Human Oncology
- **1993-1994:** Researcher with Fellowship at the University of Bari, Institute of Histology and Human Anatomy
- **1995:** CNR Fellowship for the project "BTS Biotechnologies and Biotechnical Instrumentation"
- **1995-2000:** Research Associate at The Scripps Research Institute, La Jolla - San Diego, CA, USA
- **1999-2004:** University Researcher (SSD MED/09) in Internal Medicine at the University of Bari "Aldo Moro"
- **2003-2013:** Adjunct Assistant Professor, Cancer Biology Department, Vanderbilt University, Nashville, TN
- **2004-present:** Associate Professor (SSD MED/09) in Internal Medicine at the University of Bari "Aldo Moro"
- **2016-present: Scientific Director at IRCCS "Saverio de Bellis" in Castellana Grotte**
- **2024-present: Full Professor of Internal Medicine at the University of Salento**

Clinical Activities

- **1997-2000:** Clinical Fellow, Liver Transplantation Unit, Division of Gastroenterology, La Jolla, San Diego, CA, USA
- **1999-2014:** Senior Medical Officer at Policlinico di Bari, Clinical Medical Unit "C. Frugoni"
- **2014-2016:** Senior Medical Officer at Policlinico di Bari, Clinical Medical Unit "A. Murri"
- **2016-present:** Coordination of clinical research activities at IRCCS "Saverio de Bellis", overseeing 32 interventionist clinical trials in gastroenterology and oncology

- **2018-present:** Medical Director of Phase 1 Clinical Research Unit at IRCCS “Saverio de Bellis”
- **2024:** Full Professor of Internal Medicine at the University of Salento

Fellowships in Academies and Scientific Societies

- Member of **Italian Society of Internal Medicine** since 1994
- Member of **Italian Society of Cancerology** since 2010
- Member of **Italian Society for the Study of the Liver** since 2010
- Member of **International Liver Cancer Association** since 2004
- **Italian Society of Internal Medicine - Puglia and Basilicata Section, 2007-2012** (Treasurer, Vice-President, President)

Awards and Recognition

- **1993: Best Abstract at Interferon Congress** International Symposium: 'Alpha-Interferon System lymphoblastoid: topicality and future prospects', Porto Cervo, May 1993.
- **2012:** Qualified as **Full Professor** of Internal Medicine, Gastroenterology, Infectious Diseases through national competition
- **2018: 3rd IJMS Awards** from the International Journal of Molecular Sciences
- **2019: The Most Cited Article Award** from the European Society of Clinical Investigation
- **2021: "Paladini Italiani della Salute Award** for best research published in the five-year period 2015-2020", conferred at the Capitol, RDE publishing company

C. Contributions to Science

Patents

- **2018:** Italian Patent "Method for detecting a decrease in stemness in hepatocellular carcinoma cells using a specific stemness indicator and its use in treating stem cell persistence in hepatocellular carcinoma" - Inventor
- **2022:** Italian Patent "Combination therapy of Sorafenib and/or Regorafenib with recombinant human Proteoglycan-4 for hepatocellular carcinoma treatment" - Co-Inventor
- **2024:** Italian Patent Application "Inorganic Polyphosphate as a new fecal biomarker for early diagnosis of Colorectal Cancer" - Co-Inventor

Grants and Funding (related to the last ten years)

- **2017-2024:** Responsible for Research Activities at IRCCS “Saverio de Bellis” with funding over 8.7 million euros
- **2024:** PNRR Project "Proteoglycan-4 as a coadjuvant treatment to overcome resistance to Sorafenib and Regorafenib in Hepatocellular carcinoma" - Project Coordinator (350,000 euros)
- **2024:** DIFE 2024-2026 "Salus 2.0" Project - Coordinator (300,000 euros)
- **2024:** Apulia Foundation. Notice 2024 for the implementation of large diagnostic equipment research - funding of EUR 165,000 for the purchase of an innovative platform for scanning of histological slides.
- **2024-2025:** European Commission - ERN-ApuliaMED Project - Participant Unit Leader
- **2023-2026:** Responsible, as Scientific Director of Level 1 Spoke, of the national project entitled 'PerfeTTO' (LS TTO Network) - PNC-E3-2022-23683268, national network of the Technology Transfer, with a total funding from the Ministry of Health out of 54 national spokes amounting to 15 million euro - Project Coordinator
- **2023-2025:** Ministry of Health. Project "Italian Network of Excellence for Advanced Diagnosis (INNOVA) - PNC E3-2022-23683266 - Advanced Diagnostics (HLS-DA)", funding of €713,878.00 – Role: Lead of Participating Unit (2nd level spoke).
- **2022:** Current Research Project Networks 2021 by the Ministry of Health - Aging Network "Next Generation Promising (NGP)", partner with funding of €140,000.
- **2022-2024:** Ministry of Health, Puglia Region. POS 5 Project – Project title: "IDENTITA - Integrated Mediterranean Network for the Observation and Development of Personalized Nutrition Paths against Malnutrition", Health Operational Plan, funding of €129,600.00 – Project Coordinator - Lead of Participating Unit.

- **2022-2024:** Ministry of Health – Puglia Region. POS 4 Project – Project title: "Biotechnology, Bioinformatics, and Pharmaceutical Development – HUB LIFE SCIENCES", Health Operational Plan, funding of €1,330,000.00 – Lead of Operational Unit.
- **2022-2024:** "EMOTICon-Net" Research Project - CCM 2022 Program of the Puglia Region - ARESS, Lead of Participating Unit with funding of €93,927.
- **2022:** Current Research Project Networks 2021 by the Ministry of Health – Alleanza Contro il Cancro Network (ACC) "The ACC Preclinical Research Platform for Precision Oncology", funding €36,795, Lead of Participating Unit.
- **2021:** Research Project "Development of a Platform for the Collection, Storage, and Analysis of Biological Material for Research Use" - 5x1000 funding (2021-2023) – Project Coordinator with funding of €338,190.13.
- **2021:** Donation by M.I.Cro. Italia ODV for research activities amounting to €42,000.
- **2021:** Current Research Project Networks 2021 by the Ministry of Health - Aging Network "PROMISING", partner with funding of €145,850.63.
- **2021:** Current Research Project Networks 2021 by the Ministry of Health – Alleanza Contro il Cancro Network (ACC) "National Program for Personalized Oncology", funding €11,350, Lead of Participating Unit.
- **2021-2024:** European Commission – Ministry of Health. Project titled: iParaCyts – TRANSCAN 3 ERA-NET Program, funding of €250,000 – Lead of Participating Unit.
- **2021-2025:** Investigator Grant 2020 from the Italian Association for Cancer Research (AIRC), 5-year project with funding of €578,000 – Project Coordinator.
- **2020-2022:** PON MIUR Funding – Call for the Submission of Industrial Research and Experimental Development Projects in the 12 Areas Identified by the National Research Program 2015-2020, with the project "Development of Diagnostic Biomarkers for Precision Medicine and Personalized Therapy – BIO-D", funding of €176,720 – Lead of Participating Unit.
- **2020:** Renewal of the European ERN-Apulia project (EU-H2020 MSCA-Night-2018), "European Researchers' Night" funded by Horizon 2020, with €8,000 – Project Coordinator.
- **2020:** Current Research Project Networks 2020 by the Ministry of Health – Aging Network SIRI, partner with funding of €76,500.
- **2020:** DIF 2021-2023 Research Project "Salus in Apulia", Project Coordinator with funding of €670,000.
- **2020:** Donation by M.I.Cro. Italia ODV for research activities amounting to €40,000.
- **2020:** Biogem scarl - Research Contract for the PON TerDiaMes project, with a budget of €218,000.
- **2019:** Current Research Project Networks 2019 by the Ministry of Health – Aging Network IRMA, partner with funding of €63,107.28.
- **2019:** Current Research Project Networks 2019 by the Ministry of Health – Alleanza Contro il Cancro (ACC) Network, partner with funding of €22,000.
- **2019:** Current Research Project Networks 2019 by the Ministry of Health – Alleanza Contro il Cancro (ACC) Project GERSOM, partner with funding of €75,000.
- **2019:** Donation by M.I.Cro. Italia ODV for research activities amounting to €25,000.
- **2019:** Research Project "Development of an Organoid Platform for Precision Medicine" – 5x1000 funding (2018-2020), Project Coordinator with funding of €345,558.42.
- **2019-2021:** PON MIUR Funding – Call for the Submission of Industrial Research and Experimental Development Projects in the 12 Areas Identified by the National Research Program 2015-2020, with the project "Establishment of the Human Gut and Salivary Microbiota Biobank: From Dysbiosis to Symbiosis – BIOMIS", funding of €94,000.00 – Lead of Participating Unit.
- **2018-2020:** Puglia Region FESR-FSE Operational Program 2014-2020 Action 1.6 – Innonetwork with the project "Si-Cura - Innovative Solutions for the Management of Ulcerative Colitis Patients and Therapeutic Follow-up" for €125,674.00 – Lead of Participating Unit.
- **2018-2020:** Puglia Region FESR-FSE Operational Program 2014-2020 Action 1.6 – Innonetwork with the project "Si-Ca.Re (Integrated System for Monitoring and Treating Patients with Cardio-Renal Syndrome)" aimed at defining a new hospital-territory integration model for home care of patients with heart failure and chronic renal insufficiency, funding €59,245.71 – Lead of Participating Unit.
- **2018-2020:** Puglia Region FESR-FSE Operational Program 2014-2020 Action 1.6 – Innonetwork with the project "ALTIS - Functional Food Based on Lens Culinaris, Typical of the Apulian Territory and Innovative for Health" for €72,009.43 – Lead of Participating Unit.

- **2018-2019:** European Project ERN-Apulia (EU-H2020_MSCA-Night-2018), "European Researchers' Night" funded by Horizon 2020, with €10,000 – Project Coordinator.
- **2017-2019:** "Targeting Notch Pathway for Personalizing Therapy in Cholangiocarcinoma" Investigator Grant €424,000 – Project Coordinator.
- **2017-2020:** Puglia Region – Economic Functional Guidance Document 2017 of the SSR with the project "Effect of Dietary Regimen as Therapy in Patients with NAFLD: Role of Metabolic and Microbiome Profile", funding €400,000.00 – Project Coordinator.
- **2016:** Research Project "Personalized Therapy in Patients with Liver Cancer" – 5x1000 funding (2015-2017), Project Coordinator with funding of €318,280.32.

Latest selected publications:

- 1. Review** Ricci AD, Rizzo A, Schirizzi A, D'Alessandro R, Frega G, Brandi G, Shahini E, Cozzolongo R, Lotesoriere C, **Giannelli G**. Tumor Immune Microenvironment in Intrahepatic Cholangiocarcinoma: Regulatory Mechanisms, Functions, and Therapeutic Implications. **Cancers** (Basel). **2024** Oct 20;16(20):3542. doi: 10.3390/cancers16203542. PMID: 39456636; PMCID: PMC11505966. **IF=4.9**
- 2. Article** Mancarella S, Gigante I, Pizzuto E, Serino G, Terzi A, Dituri F, Maiorano E, Vincenti L, De Bellis M, Ardito F, Calvisi DF, **Giannelli G**. Targeting cancer-associated fibroblasts/tumor cells cross-talk inhibits intrahepatic cholangiocarcinoma progression via cell-cycle arrest. **J Exp Clin Cancer Res**. **2024** Oct 17;43(1):286. doi: 10.1186/s13046-024-03210-9. PMID: 39415286; PMCID: PMC11484308. **IF=11.4**
- 3. Review** Laface C, Ricci AD, Vallarelli S, Ostuni C, Rizzo A, Ambrogio F, Centonze M, Schirizzi A, De Leonardis G, D'Alessandro R, Lotesoriere C, **Giannelli G**. Autotaxin-Lysophosphatidate Axis: Promoter of Cancer Development and Possible Therapeutic Implications. **Int J Mol Sci**. **2024** Jul 15;25(14):7737. doi: 10.3390/ijms25147737. PMID: 39062979; PMCID: PMC11277072. **IF=4.9**
- 4. Review** Quaranta V, Ballarò C, **Giannelli G**. Macrophages Orchestrate the Liver Tumor Microenvironment. **Cancers** (Basel). **2024** May 4;16(9):1772. doi: 10.3390/cancers16091772. PMID: 38730724; PMCID: PMC11083142. **IF=4.9**
- 5. Review** Ballarò C, Quaranta V, **Giannelli G**. Colorectal Liver Metastasis: Can Cytokines Make the Difference? **Cancers** (Basel). **2023** Nov 10;15(22):5359. doi: 10.3390/cancers15225359. PMID: 38001618; PMCID: PMC10670198. **IF=4.9**
- 6. Article** Lacalamita A, Serino G, Pantaleo E, Monaco A, Amoroso N, Bellantuono L, Piccinno E, Scalavino V, Dituri F, Tangaro S, Bellotti R, **Giannelli G**. Artificial Intelligence and Complex Network Approaches Reveal Potential Gene Biomarkers for Hepatocellular Carcinoma. **Int J Mol Sci**. **2023** Oct 18;24(20):15286. doi: 10.3390/ijms242015286. PMID: 37894965; PMCID: PMC10607580. **IF=4.9**
- 7. Article** Centonze M, Di Conza G, Lahn M, Fabregat I, Dituri F, Gigante I, Serino G, Scialpi R, Carrieri L, Negro R, Pizzuto E, **Giannelli G**. Autotaxin inhibitor IOA-289 reduces gastrointestinal cancer progression in preclinical models. **J Exp Clin Cancer Res**. **2023** Aug 8;42(1):197. doi: 10.1186/s13046-023-02780-4. Erratum in: **J Exp Clin Cancer Res**. **2023** Aug 18;42(1):211. doi: 10.1186/s13046-023-02797-9. PMID: 37550785; PMCID: PMC10408149. **IF=11.4**
- 8. Review** Shahini E, Pasculli G, Solimando AG, Tiribelli C, Cozzolongo R, **Giannelli G**. Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review. **Int J Mol Sci**. **2023** Feb 21;24(5):4286. doi: 10.3390/ijms24054286. PMID: 36901717; PMCID: PMC10001986. **IF=4.9**
- 9. Article** Mancarella S, Serino G, Gigante I, Cigliano A, Ribback S, Sanese P, Grossi V, Simone C, Armentano R, Evert M, Calvisi DF, **Giannelli G**. Correction: CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype. **J Exp Clin Cancer Res**. **2023** Apr 18;42(1):88. doi: 10.1186/s13046-023-02661-w. Erratum for: **J Exp Clin Cancer Res**. **2022** Feb 16;41(1):65. doi: 10.1186/s13046-022-02283-8. PMID: 37069577; PMCID: PMC10111764. **IF=11.4**
- 10. Article** Mancarella S, Gigante I, Serino G, Pizzuto E, Dituri F, Valentini MF, Wang J, Chen X, Armentano R, Calvisi DF, **Giannelli G**. Crenigacestat blocking notch pathway reduces liver fibrosis in the surrounding ecosystem of intrahepatic CCA via TGF- β inhibition. **J Exp Clin Cancer Res**. **2022** Nov 28;41(1):331. doi: 10.1186/s13046-022-02536-6. PMID: 36443822; PMCID: PMC9703776. **IF=11.4**
- 11. Article** Mancarella S, Serino G, Coletta S, Armentano R, Dituri F, Ardito F, Ruzzenente A, Fabregat I, **Giannelli G**. The Tumor Microenvironment Drives Intrahepatic Cholangiocarcinoma Progression. **Int J Mol Sci**. **2022** Apr 10;23(8):4187. doi: 10.3390/ijms23084187. PMID: 35457006; PMCID: PMC9032805. **IF=4.9**
- 12. Article** Dituri F, Mancarella S, Serino G, Chaoul N, Lupo LG, Villa E, Fabregat I, **Giannelli G**. Direct and Indirect Effect of TGF β on Treg Transendothelial Recruitment in HCC Tissue Microenvironment. **Int J Mol Sci**. **2021** Oct 29;22(21):11765. doi: 10.3390/ijms222111765. PMID: 34769191; PMCID: PMC8583957. **IF=4.9**
- 13. Article** Scavo MP, Rizzi F, Depalo N, Armentano R, Coletta S, Serino G, Fanizza E, Pesole PL, Cervellera A, Carella N, Curri ML, **Giannelli G**. Exosome Released FZD10 Increases Ki-67 Expression via Phospho-ERK1/2 in Colorectal and Gastric Cancer. **Front Oncol**. **2021** Sep 23;11:730093. doi: 10.3389/fonc.2021.730093. PMID: 34671555; PMCID: PMC8522497. **IF=3.5**

- 14. Article** Dituri F, Scialpi R, Schmidt TA, Frusciante M, Mancarella S, Lupo LG, Villa E, Giannelli G. Proteoglycan-4 is correlated with longer survival in HCC patients and enhances sorafenib and regorafenib effectiveness via CD44 in vitro. *Cell Death Dis.* 2020 Nov 16;11(11):984. doi: 10.1038/s41419-020-03180-8. PMID: 33199679; PMCID: PMC7669886. **IF=8.1**
- 15. Article** Scavo MP, Rizzi F, Depalo N, Fanizza E, Ingrosso C, Curri ML, Giannelli G. A Possible Role of FZD10 Delivering Exosomes Derived from Colon Cancers Cell Lines in Inducing Activation of Epithelial-Mesenchymal Transition in Normal Colon Epithelial Cell Line. *Int J Mol Sci.* 2020 Sep 13;21(18):6705. doi: 10.3390/ijms21186705. PMID: 32933173; PMCID: PMC7555665. **IF=4.9**
- 16. Article** Mancarella S, Serino G, Dituri F, Cigliano A, Ribback S, Wang J, Chen X, Calvisi DF, **Giannelli G.** Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis. *Cell Death Differ.* 2020 Aug;27(8):2330-2343. doi: 10.1038/s41418-020-0505-4. Epub 2020 Feb 10. PMID: 32042099; PMCID: PMC7370218. **IF=13.7**
- 17. Review** Mancarella S, Krol S, Crovace A, Leporatti S, Dituri F, Frusciante M, **Giannelli G.** Validation of Hepatocellular Carcinoma Experimental Models for TGF- β Promoting Tumor Progression. *Cancers (Basel).* 2019 Oct 9;11(10):1510. doi: 10.3390/cancers11101510. PMID: 31600917; PMCID: PMC6826694. **IF=4.9**
- 18. Article** Kelley RK, Gane E, Assenat E, Siebler J, Galle PR, Merle P, Hourmand IO, Cleverly A, Zhao Y, Gueorguieva I, Lahn M, Faivre S, Benhadji KA, Giannelli G. A Phase 2 Study of Galunisertib (TGF- β 1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. *Clin Transl Gastroenterol.* 2019 Jul;10(7):e00056. doi: 10.14309/ctg.0000000000000056. PMID: 31295152; PMCID: PMC6708671. **IF=3**
- 19. Article** Faivre S, Santoro A, Kelley RK, Gane E, Costentin CE, Gueorguieva I, Smith C, Cleverly A, Lahn MM, Raymond E, Benhadji KA, **Giannelli G.** Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma. *Liver Int.* 2019 Aug;39(8):1468-1477. doi: 10.1111/liv.14113. Epub 2019 Jun 3. PMID: 30963691. **IF=6**
- 20. Article** Rani B, Malfettone A, Dituri F, Soukupova J, Lupo L, Mancarella S, Fabregat I, **Giannelli G.** Galunisertib suppresses the staminal phenotype in hepatocellular carcinoma by modulating CD44 expression. *Cell Death Dis.* 2018 Mar 7;9(3):373. doi: 10.1038/s41419-018-0384-5. PMID: 29515105; PMCID: PMC5841307. **IF=8.1**
- 21. Article** Notarnicola M, Lorusso D, Tutino V, De Nunzio V, De Leonardi G, Marangelli G, Guerra V, Veronese N, Caruso MG, Giannelli G. Differential Tissue Fatty Acids Profiling between Colorectal Cancer Patients with and without Synchronous Metastasis. *Int J Mol Sci.* 2018 Mar 23;19(4):962. doi: 10.3390/ijms19040962. PMID: 29570667; PMCID: PMC5979339. **IF=4.9**
- 22. Article** Agarwal R, Cao Y, Hoffmeier K, Krezdorn N, Jost L, Meisel AR, Jüngling R, Dituri F, Mancarella S, Rotter B, Winter P, **Giannelli G.** Precision medicine for hepatocellular carcinoma using molecular pattern diagnostics: results from a preclinical pilot study. *Cell Death Dis.* 2017 Jun 8;8(6):e2867. doi: 10.1038/cddis.2017.229. PMID: 28594404; PMCID: PMC5520889. **IF=8.1**
- 23. Article** Cao Y, Agarwal R, Dituri F, Lupo L, Trerotoli P, Mancarella S, Winter P, **Giannelli G.** NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF- β receptor blocker galunisertib in HCC. *Cell Death Dis.* 2017 Feb 23;8(2):e2634. doi: 10.1038/cddis.2017.44. PMID: 28230858; PMCID: PMC5386488. **IF=8.1**
- 24. Article** Notarnicola M, Tutino V, De Nunzio V, Dituri F, Caruso MG, **Giannelli G.** Dietary ω -3 Polyunsaturated Fatty Acids Inhibit Tumor Growth in Transgenic Apc^{Min/+} Mice, Correlating with CB1 Receptor Up-Regulation. *Int J Mol Sci.* 2017 Feb 24;18(3):485. doi: 10.3390/ijms18030485. PMID: 28245562; PMCID: PMC5372501. **IF=4.9**
- 25. Article** Azzariti A, Mancarella S, Porcelli L, Quatrone AE, Caligiuri A, Lupo L, Dituri F, **Giannelli G.** Hepatic stellate cells induce hepatocellular carcinoma cell resistance to sorafenib through the laminin-332/ α 3 integrin axis recovery of focal adhesion kinase ubiquitination. *Hepatology.* 2016 Dec;64(6):2103-2117. doi: 10.1002/hep.28835. Epub 2016 Oct 27. PMID: 27639064. **IF=13**
- 26. Review** **Giannelli G,** Koudelkova P, Dituri F, Mikulits W. Role of epithelial to mesenchymal transition in hepatocellular carcinoma. *J Hepatol.* 2016 Oct;65(4):798-808. doi: 10.1016/j.jhep.2016.05.007. Epub 2016 May 17. PMID: 27212245. **IF=26.8**
- 27. Review** **Giannelli G,** Mikulits W, Dooley S, Fabregat I, Moustakas A, ten Dijke P, Portincasa P, Winter P, Janssen R, Leporatti S, Herrera B, Sanchez A. The rationale for targeting TGF- β in chronic liver diseases. *Eur J Clin Invest.* 2016 Apr;46(4):349-61. doi: 10.1111/eci.12596. Epub 2016 Mar 12. PMID: 26823073. **IF=4.4**

Declaration

I, Gianluigi Giannelli, aware that false statements may result in penalties under Article 76 of Presidential Decree 445/2000, declare that the information provided in this CV, made under a substitute declaration of truth as per Articles 46 and 47 of Presidential Decree 445/2000, is true. A valid ID document is attached.

Castellana Grotte, 09/12/2024
Prof. Gianluigi Giannelli

